Orion Oyj B (ORNBV)

Currency in EUR
70.30
+0.35(+0.50%)
Real-time Data·
ORNBV Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
ORNBV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
69.8070.65
52 wk Range
41.3571.85
Key Statistics
Prev. Close
69.95
Open
70
Day's Range
69.8-70.65
52 wk Range
41.35-71.85
Volume
5.98K
Average Volume (3m)
238.38K
1-Year Change
69.62%
Book Value / Share
6.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORNBV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
66.75
Downside
-5.05%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Orion Oyj B News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Orion Oyj B Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other companies. It has discovery service and commercial license agreement with Invenra to develop bispecific antibody cancer therapeutics; and collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.

Employees
3700
Market
Finland

Orion Oyj B Earnings Call Summary for Q2/2025

  • Q2 net sales reached €416.5M (+27% YoY), surpassing forecasts; operating profit up 59% to €104.5M
  • FDA approval of darolutamide strengthens product pipeline; stock price rose 4.31% near 52-week high
  • Full-year 2025 guidance: net sales €1,630-1,730M, operating profit €400-500M
  • CEO highlights Nubeqa's importance and commitment to innovation; plans for clinical pipeline expansion
  • Potential risks: U.S. pharma tariffs, competitive pressures in generics market, macroeconomic uncertainties
Last Updated: 18/07/2025, 12:30
Read Full Transcript

Compare ORNBV to Peers and Sector

Metrics to compare
ORNBV
Peers
Sector
Relationship
P/E Ratio
26.0x17.8x−0.5x
PEG Ratio
0.411.020.00
Price/Book
10.7x2.4x2.6x
Price / LTM Sales
5.9x2.3x3.2x
Upside (Analyst Target)
2.9%10.2%41.2%
Fair Value Upside
Unlock20.0%6.2%Unlock

Analyst Ratings

4 Buy
1 Hold
2 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 66.75
(-5.05% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.69%
Dividend Yield
2.34%
Industry Median 2.35%
Annualised payout
1.64
Paid unevenly
5-Years Growth
+1.80%
Growth Streak

Earnings

Latest Release
Jul 18, 2025
EPS / Forecast
0.59 / 0.5179
Revenue / Forecast
416.50M / 380.43M
EPS Revisions
Last 90 days

ORNBV Income Statement

People Also Watch

24.34
UPM
-0.37%
12.675
NDAFI
+0.52%
19.33
KESKOB
-0.21%
62.260
CRDI
+0.94%
442.7
NOVOb
-1.87%

FAQ

What Stock Exchange Does Orion Oyj B Trade On?

Orion Oyj B is listed and trades on the Helsinki Stock Exchange stock exchange.

What Is the Stock Symbol for Orion Oyj B?

The stock symbol for Orion Oyj B is "ORNBV."

What Is the Orion Oyj B Market Cap?

As of today, Orion Oyj B market cap is 9.94B.

What Is Orion Oyj B's Earnings Per Share (TTM)?

The Orion Oyj B EPS (TTM) is 2.69.

When Is the Next Orion Oyj B Earnings Date?

Orion Oyj B will release its next earnings report on 27 Oct 2025.

From a Technical Analysis Perspective, Is ORNBV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Orion Oyj B Stock Split?

Orion Oyj B has split 0 times.

How Many Employees Does Orion Oyj B Have?

Orion Oyj B has 3700 employees.

What is the current trading status of Orion Oyj B (ORNBV)?

As of 29 Jul 2025, Orion Oyj B (ORNBV) is trading at a price of 70.30, with a previous close of 69.95. The stock has fluctuated within a day range of 69.80 to 70.65, while its 52-week range spans from 41.35 to 71.85.

What Is Orion Oyj B (ORNBV) Price Target According to Analysts?

The average 12-month price target for Orion Oyj B is EUR66.75, with a high estimate of EUR77 and a low estimate of EUR46. 4 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an -5.05% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.